GMEX ROBOTICS CORPORATION - Class A Ordinary Shares (GMEX)

The oral thin film drug delivery market is entering a high-growth phase, with industry forecasts projecting expansion from $3.30 billion in 2025 to $5.21 billion by 2030, representing a 9.56% CAGR . As demand accelerates for faster, more efficient drug delivery systems , companies positioned at the forefront of this innovation—such as Rapid Dose Therapeutics (CSE: DOSE) (OTCQB: RDTCF)—are increasingly drawing investor attention.

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of GMEX Robotics Corp. (NASDAQ: GMEX) resulting from allegations that GMEX may have issued materially misleading business information to the investing public.

ADM Endeavors (OTCQB: ADMQ) is beginning to attract increased investor attention following a 67% move off its March 2026 levels, as the company enters what could be a defining phase of operational scale driven by infrastructure expansion, brand growth, and entry into larger addressable markets.